Connecting clinical trial testing and advanced diagnostic capabilities to accelerate patient access to therapies

Recognizing that Labcorp was uniquely positioned to integrate drug development and diagnostic solutions, a global pharmaceutical sponsor asked Labcorp to seamlessly support their entire rare disease portfolio - from nonclinical research to clinical trial testing along with the development of companion diagnostics (CDx) to capitalize on their biomarker strategy and identify the right patients for therapy post-FDA approval.

Copy and paste this URL:

https://biopharma.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/casestudies/610907_DD_CS_RareDisease_FINAL.pdf